NBT Bank N.A. Buys 7,751 Shares of Gilead Sciences, Inc. $GILD

NBT Bank N.A. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, Holdings Channel.com reports. The firm bought 7,751 shares of the biopharmaceutical company’s stock, valued at approximately $1,155,000.

A number of other institutional investors have also added to or reduced their stakes in GILD. BlackRock Inc. purchased a new stake in Gilead Sciences during the second quarter valued at about $15,393,785,000. State Street Corp boosted its holdings in shares of Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares in the last quarter. Amundi boosted its holdings in shares of Gilead Sciences by 10.7% in the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after purchasing an additional 1,018,976 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $1,316,606,000. Finally, Deutsche Bank AG bought a new position in shares of Gilead Sciences during the 2nd quarter valued at about $918,387,000. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of research reports. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $160.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Jefferies Financial Group restated a “buy” rating and issued a $185.00 target price on shares of Gilead Sciences in a research report on Friday. Truist Financial upped their target price on Gilead Sciences from $150.00 to $158.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. HSBC increased their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Barclays decreased their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $159.81.

Gilead Sciences Stock Down 0.7%

Shares of Gilead Sciences stock opened at $156.04 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a 52-week low of $114.02 and a 52-week high of $160.51. The stock has a market capitalization of $193.48 billion, a price-to-earnings ratio of -58.44 and a beta of 0.31. The company’s 50 day moving average price is $149.10 and its 200-day moving average price is $137.85.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.01 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, September 15th. Gilead Sciences’s payout ratio is presently -122.85%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Inflammation pipeline expanded: Gilead agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash. The drug is intended for inflammatory bowel disease and could be developed alone or alongside Gilead’s emvistegrast, strengthening the company’s longer-term growth prospects. Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001
• Positive Sentiment: HIV development update: An ongoing study of a potential weekly oral HIV treatment adds another option to Gilead’s long-acting HIV portfolio. Positive clinical progress could support the company’s dominant HIV franchise and future revenue durability. Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower
• Positive Sentiment: Oncology collaboration: BioNTech and Gilead will test Gilead’s sacituzumab govitecan with BioNTech’s pumitamig in a global Phase 3 trial for advanced triple-negative breast cancer. The collaboration may improve the commercial potential of Gilead’s oncology platform, although clinical success remains uncertain. BioNTech, Gilead to Test Drug Combination
• Positive Sentiment: Favorable analyst and earnings expectations: TD Cowen reiterated a Buy view, while analysts indicated that Gilead could beat expectations in its upcoming quarterly report. Such forecasts support sentiment, though they are not guarantees of results. Gilead Sciences Receives a Buy from TD Cowen
• Neutral Sentiment: Gilead plans to present new data on rare liver diseases at The Liver Meeting 2026. The presentations could generate future catalysts, but no immediate clinical results were reported. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Legal overhang: Gilead will pay $45 million to settle Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines. The financial cost is modest relative to Gilead’s size, but the settlement adds regulatory and reputational risk. Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director owned 12,894 shares of the company’s stock, valued at $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.